533 related articles for article (PubMed ID: 31856368)
1. Efficacy of dupilumab in prurigo nodularis in elderly patient.
Giura MT; Viola R; Fierro MT; Ribero S; Ortoncelli M
Dermatol Ther; 2020 Jan; 33(1):e13201. PubMed ID: 31856368
[TBL] [Abstract][Full Text] [Related]
2. Validation of Psychometric Properties of the Itch Numeric Rating Scale for Pruritus Associated With Prurigo Nodularis: A Secondary Analysis of a Randomized Clinical Trial.
Kimel M; Zeidler C; Kwon P; Revicki D; Ständer S
JAMA Dermatol; 2020 Dec; 156(12):1354-1358. PubMed ID: 32936233
[TBL] [Abstract][Full Text] [Related]
3. Dupilumab in prurigo nodularis: a systematic review of current evidence and analysis of predictive factors to response.
Husein-ElAhmed H; Steinhoff M
J Dermatolog Treat; 2022 May; 33(3):1547-1553. PubMed ID: 33200955
[TBL] [Abstract][Full Text] [Related]
4. Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis.
Ständer S; Yosipovitch G; Legat FJ; Lacour JP; Paul C; Narbutt J; Bieber T; Misery L; Wollenberg A; Reich A; Ahmad F; Piketty C
N Engl J Med; 2020 Feb; 382(8):706-716. PubMed ID: 32074418
[TBL] [Abstract][Full Text] [Related]
5. A critical review of dupilumab for adult patients with prurigo nodularis.
Biazus Soares G; Yosipovitch G
Expert Rev Clin Immunol; 2024 Mar; 20(3):249-254. PubMed ID: 37811660
[TBL] [Abstract][Full Text] [Related]
6. The effectiveness and safety of dupilumab in the management of refractory prurigo nodularis in 45 Chinese patients: A real-life observational study.
Fang HY; Lian CH
J Dermatol; 2023 Aug; 50(8):1084-1087. PubMed ID: 37088954
[TBL] [Abstract][Full Text] [Related]
7. A real-world observational study of dupilumab treatment in adult patients with prurigo nodularis.
Zhang Z; Li S; Wang Y; Zhao J
An Bras Dermatol; 2023; 98(4):440-448. PubMed ID: 36966024
[TBL] [Abstract][Full Text] [Related]
8. Dupilumab for the treatment of prurigo nodularis: A systematic review.
Cao P; Xu W; Jiang S; Zhang L
Front Immunol; 2023; 14():1092685. PubMed ID: 36742321
[TBL] [Abstract][Full Text] [Related]
9. Nemolizumab efficacy in prurigo nodularis: onset of action on itch and sleep disturbances.
Ständer S; Yosipovitch G; Lacour JP; Legat FJ; Paul C; Reich A; Chaouche K; Ahmad F; Piketty C
J Eur Acad Dermatol Venereol; 2022 Oct; 36(10):1820-1825. PubMed ID: 35766128
[TBL] [Abstract][Full Text] [Related]
10. The Sleep Disturbance Numerical Rating Scale: Content Validity, Psychometric Validation, and Meaningful Within-Patient Change in Prurigo Nodularis.
Ständer S; Fofana F; Dias-Barbosa C; Rodriguez D; Budhiarso I; Jabbar-Lopez ZK; Piketty C; Vernon M; Puelles J
Dermatol Ther (Heidelb); 2023 Jul; 13(7):1587-1602. PubMed ID: 37329468
[TBL] [Abstract][Full Text] [Related]
11. Successful Treatment of Prurigo Nodularis by Dupilumab: Report of 24 Patients.
Gao Z; Dou Y; Zhao P; Wang CJ; Zhang J
Dermatology; 2023; 239(4):658-663. PubMed ID: 37011607
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of dupilumab in chronic prurigo and chronic idiopathic pruritus: a systematic review of current evidence and analysis of response predictors.
Gael M; Adam T; Mariano-Bourin M; Bursztejn AC
J Eur Acad Dermatol Venereol; 2022 Sep; 36(9):1541-1551. PubMed ID: 35569006
[TBL] [Abstract][Full Text] [Related]
13. Validation of the Peak Pruritus Numerical Rating Scale as a Patient-Reported Outcome Measure in Prurigo Nodularis.
Kwatra SG; Rodriguez D; Dias-Barbosa C; Budhiarso I; Fofana F; Vernon M; Gabriel S; Piketty C; Puelles J
Dermatol Ther (Heidelb); 2023 Oct; 13(10):2403-2416. PubMed ID: 37615836
[TBL] [Abstract][Full Text] [Related]
14. Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis.
Kwatra SG; Yosipovitch G; Legat FJ; Reich A; Paul C; Simon D; Naldi L; Lynde C; De Bruin-Weller MS; Nahm WK; Sauder M; Gharib R; Barbarot S; Szepietowski JC; Conrad C; Fleischer A; Laquer VT; Misery L; Serra-Baldrich E; Lapeere H; Ahmad F; Jabbar Lopez ZK; Piketty C; Ständer S;
N Engl J Med; 2023 Oct; 389(17):1579-1589. PubMed ID: 37888917
[TBL] [Abstract][Full Text] [Related]
15. Dupilumab and prurigo nodularis-like phenotype in atopic dermatitis: our experience of efficacy.
Ferrucci S; Tavecchio S; Berti E; Angileri L
J Dermatolog Treat; 2021 Jun; 32(4):453-454. PubMed ID: 31442084
[TBL] [Abstract][Full Text] [Related]
16. Dupilumab for the Treatment of Prurigo Nodularis.
Alkhaleefa A; Woo TE; Parsons L
Skin Therapy Lett; 2023 Nov; 28(6):7-9. PubMed ID: 38016088
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study.
Sofen H; Bissonnette R; Yosipovitch G; Silverberg JI; Tyring S; Loo WJ; Zook M; Lee M; Zou L; Jiang GL; Paolini JF
EClinicalMedicine; 2023 Mar; 57():101826. PubMed ID: 36816342
[TBL] [Abstract][Full Text] [Related]
18. Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials.
Yosipovitch G; Mollanazar N; Ständer S; Kwatra SG; Kim BS; Laws E; Mannent LP; Amin N; Akinlade B; Staudinger HW; Patel N; Yancopoulos GD; Weinreich DM; Wang S; Shi G; Bansal A; O'Malley JT
Nat Med; 2023 May; 29(5):1180-1190. PubMed ID: 37142763
[TBL] [Abstract][Full Text] [Related]
19. Dupilumab for pediatric prurigo nodularis: A case report.
Fachler T; Maria Faitataziadou S; Molho-Pessach V
Pediatr Dermatol; 2021 Jan; 38(1):334-335. PubMed ID: 33247435
[TBL] [Abstract][Full Text] [Related]
20. Dupilumab for Chronic Prurigo: Case Series on Effectiveness, Safety, and Quality of Life.
Richter C; Hafner J; Schuermann M; Tanadini M; Trisconi N; Schmid-Grendelmeier P; Kündig T; Nägeli M; Brüggen MC; Guillet C
Dermatology; 2023; 239(5):811-817. PubMed ID: 37369187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]